Sartorius Intensifies Biopharma Strategy with Ambitious Growth Targets

Sartorius, a prominent life science group, is enhancing its strategy to focus on the growing biopharmaceutical sector. The company aims to bolster its competitive edge in high-growth, high-margin segments, setting ambitious mid-term targets for sustainable, profitable growth that surpasses market averages.

CEO Dr. Michael Grosse emphasizes the critical role of focus amid the current demanding phase of the biopharma industry. Sartorius intends to reinforce its core competencies and elevate customer experience and operational efficiency to consistently outperform the market and create value across its ecosystem.

The firm has laid out strategic initiatives to advance its product offerings in key areas such as process intensification and single-use technologies. It also seeks to improve customer relationships by enhancing supply chain performance and service levels.

Looking forward to 2027, Sartorius forecasts organic sales revenue growth of 8% to 11% annually at the group level, driven by both Bioprocess Solutions and Lab Products & Services divisions, with a focus on margin expansion.